Pharsight

1. Abelcet patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5616334	LEADIANT BIOSCI INC	Low toxicity drug-lipid systems	Apr, 2014 (10 years ago)

Drugs and Companies using AMPHOTERICIN B ingredient

Market Authorisation Date: 20 November, 1995

Treatment: NA

Dosage: INJECTABLE, LIPID COMPLEX;INJECTION

Strength	Dosage	Availability
5MG/ML	INJECTABLE, LIPID COMPLEX;INJECTION	Prescription

ABELCET family patents

2. Abilify patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5006528	OTSUKA	Carbostyril derivatives	Oct, 2014 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
Pediatric Exclusivity(PED)	Aug 27, 2011
Orphan Drug Exclusivity(ODE)	Dec 12, 2021
M(M-137)	Jun 09, 2017
New Indication(I-700)	Dec 12, 2017
Orphan Drug Exclusivity(ODE-80)	Dec 12, 2021
New Indication(I-633)	Feb 16, 2014

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 07 June, 2006

Treatment: Treatment of schizophrenia including maintaining stability in patients with schizophrenia

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL; SOLUTION;ORAL; INJECTABLE;INTRAMUSCULAR; TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	Last patent expiry	180 day status
1 mg/mL	20 Dec, 2007	1	24 Apr, 2022	Extinguished
2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg	15 Nov, 2006	8	20 Oct, 2014	Extinguished
10 mg, 15 mg, 20 mg and 30 mg	15 Nov, 2006	1	20 Oct, 2014	Extinguished

Strength	Dosage	Availability
15MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
30MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
20MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
1MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SOLUTION;ORAL	Discontinued
9.75MG/1.3ML (7.5MG/ML)	INJECTABLE;INTRAMUSCULAR	Discontinued
30MG	TABLET;ORAL	Prescription
2MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
15MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
10MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued

ABILIFY family patents

3. Abilify Maintena Kit patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5006528	OTSUKA PHARM CO LTD	Carbostyril derivatives	Oct, 2014 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-746)	Jul 27, 2020
New Dosage Form(NDF)	Feb 28, 2016
M(M-150)	Dec 05, 2017

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: Treatment of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
300 mg/vial and 400 mg/vial	20 Dec, 2021	1		24 Sep, 2033

Strength	Dosage	Availability
400MG	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
300MG	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
400MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
300MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

ABILIFY MAINTENA KIT family patents

4. Alinia patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6020353	ROMARK	2-(hydroxy)-N-(5-nitro-2-thiazolyl) benzamide	Sep, 2014 (9 years ago)

Drugs and Companies using NITAZOXANIDE ingredient

Market Authorisation Date: 21 July, 2004

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
500MG	TABLET;ORAL	Prescription

ALINIA family patents

5. Allegra patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7135571	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)
US7138524	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)

Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 July, 1996

Treatment: NA

Dosage: CAPSULE;ORAL; SUSPENSION;ORAL

Strength	Dosage	Availability
60MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE;ORAL	Discontinued
30MG/5ML	SUSPENSION;ORAL	Discontinued

ALLEGRA family patents

6. Allegra Allergy patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7135571	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)
US7138524	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)

Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 January, 2011

Treatment: Relief of symptoms associated with respiratory allergies and for the relief of symptoms associated with hives (urticaria) in adults and children 6 years of age and older and 12 years of age and older

Dosage: TABLET;ORAL

Strength	Dosage	Availability
180MG	TABLET;ORAL	Over the counter
60MG	TABLET;ORAL	Over the counter

ALLEGRA ALLERGY family patents

7. Allegra Hives patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7135571	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)
US7138524	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)

Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 January, 2011

Dosage: TABLET;ORAL

Strength	Dosage	Availability
60MG	TABLET;ORAL	Discontinued
180MG	TABLET;ORAL	Over the counter

ALLEGRA HIVES family patents

8. Allegra-d 12 Hour Allergy And Congestion patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7135571	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)
US7138524	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)

Drugs and Companies using FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 January, 2011

Treatment: Relief of symptoms associated with respiratory allergies, swelling of the nasal passages and sinus congestion and pressure in adults and children 12 years of age and older

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
60MG;120MG	TABLET, EXTENDED RELEASE;ORAL	Over the counter

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION family patents

9. Allegra-d 24 Hour Allergy And Congestion patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7138524	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)

Drugs and Companies using FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 January, 2011

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
180 mg/240 mg	06 Jun, 2007	1	22 Jun, 2011	25 Dec, 2020	Eligible

Strength	Dosage	Availability
180MG;240MG	TABLET, EXTENDED RELEASE;ORAL	Over the counter

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION family patents

10. Amitiza patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5284858	SUCAMPO PHARMA LLC	Prostaglandins E and anti ulcers containing same	Jul, 2014 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-225)	Apr 26, 2021
New Indication(I-670)	Apr 19, 2016

Drugs and Companies using LUBIPROSTONE ingredient

Market Authorisation Date: 29 April, 2008

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
8 mcg and 24 mcg	20 Aug, 2012	1	27 Jun, 2022	30 Aug, 2022	Extinguished

Strength	Dosage	Availability
8MCG	CAPSULE;ORAL	Prescription
24MCG	CAPSULE;ORAL	Prescription

AMITIZA family patents

11. Angiomax patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5196404	SANDOZ	Inhibitors of thrombin	Dec, 2014 (9 years ago)

Drugs and Companies using BIVALIRUDIN ingredient

Market Authorisation Date: 15 December, 2000

Treatment: Inhibition of thrombin in a patient

Dosage: INJECTABLE;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
250 mg/vial	01 Sep, 2009	1		27 Jul, 2028	Extinguished

Strength	Dosage	Availability
250MG/VIAL	INJECTABLE;INTRAVENOUS	Prescription

ANGIOMAX family patents

12. Aptivus patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6169181	BOEHRINGER INGELHEIM	Compounds useful to treat retroviral infections	May, 2014 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
Pediatric Exclusivity(PED)	Dec 23, 2011

Drugs and Companies using TIPRANAVIR ingredient

Market Authorisation Date: 22 June, 2005

Treatment: NA

Dosage: CAPSULE;ORAL; SOLUTION;ORAL

Strength	Dosage	Availability
250MG	CAPSULE;ORAL	Prescription
100MG/ML	SOLUTION;ORAL	Discontinued

APTIVUS family patents

13. Children's Allegra Allergy patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7138524	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)
US7135571	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)

Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 January, 2011

Dosage: SUSPENSION;ORAL; TABLET, ORALLY DISINTEGRATING;ORAL; TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
30 mg/5 mL	25 Jan, 2010	1	18 Nov, 2014	14 Mar, 2017	Eligible
30 mg, 60 mg and 180 mg

Strength	Dosage	Availability
30MG/5ML	SUSPENSION;ORAL	Over the counter
30MG	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
30MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued

CHILDREN'S ALLEGRA ALLERGY family patents

14. Children's Allegra Hives patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7138524	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)
US7135571	CHATTEM SANOFI	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof	May, 2014 (9 years ago)

Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 January, 2011

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL; SUSPENSION;ORAL; TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
30 mg/5 mL	25 Jan, 2010	1	18 Nov, 2014	14 Mar, 2017	Eligible
30 mg, 60 mg and 180 mg

Strength	Dosage	Availability
30MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, ORALLY DISINTEGRATING;ORAL	Discontinued
30MG/5ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SUSPENSION;ORAL	Discontinued
30MG	TABLET;ORAL	Discontinued

CHILDREN'S ALLEGRA HIVES family patents

15. Copaxone patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6939539	TEVA PHARMS USA	Copolymer-1 improvements in compositions of copolymers	May, 2014 (9 years ago)
US6620847	TEVA PHARMS USA	Copolymer-1 improvements in compositions of copolymers	May, 2014 (9 years ago)
US6362161	TEVA PHARMS USA	Copolymer-1 improvements on compositions of copolymers	May, 2014 (9 years ago)
US8367605	TEVA PHARMS USA	Copolymer-1 improvements in compositions of copolymers	May, 2014 (9 years ago)
US7199098	TEVA PHARMS USA	Copolymer-1 improvements in compositions of copolymers	May, 2014 (9 years ago)
US6054430	TEVA PHARMS USA	Copolymer-1 improvements in compositions of copolymers	May, 2014 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jan 28, 2017
New Indication(I-594)	Feb 27, 2012

Drugs and Companies using GLATIRAMER ACETATE ingredient

Market Authorisation Date: 20 December, 1996

Treatment: NA

Dosage: FOR SOLUTION;SUBCUTANEOUS; INJECTABLE;SUBCUTANEOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
20 mg/mL, 1mL pre- filled syringe	27 Dec, 2007	1	16 Apr, 2015	24 May, 2014	Extinguished
40 mg/mL, 1 mL pre- filled syringe	26 Feb, 2014	2	03 Oct, 2017	19 Aug, 2030	Deferred

Strength	Dosage	Availability
20MG/VIAL	FOR SOLUTION;SUBCUTANEOUS	Discontinued
40MG/ML	INJECTABLE;SUBCUTANEOUS	Prescription
20MG/ML	INJECTABLE;SUBCUTANEOUS	Prescription

COPAXONE family patents

16. Duac patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5466446	STIEFEL	Topical compositions containing bensoyl peroxide and clindamycin and method of use thereof	Feb, 2014 (10 years ago)

Drugs and Companies using BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 26 August, 2002

Treatment: NA

Dosage: GEL;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1% / 5%	11 Dec, 2008	1	26 Jun, 2012	14 Nov, 2012	Deferred

Strength	Dosage	Availability
5%;1.2%	GEL;TOPICAL	Prescription

DUAC family patents

17. Ertaczo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5135943	LACER PHARMA	1H-imidazole derivative compounds and pharmaceutical compositions containing the same	May, 2014 (9 years ago)

Drugs and Companies using SERTACONAZOLE NITRATE ingredient

Market Authorisation Date: 10 December, 2003

Treatment: Product is approved for the topical treatment of tinea pedis

Dosage: CREAM;TOPICAL

ERTACZO family patents

18. Exelon patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5602176	SANDOZ	Phenyl carbamate	Feb, 2014 (10 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jun 27, 2016
New Strength(NS)	Aug 31, 2015

Drugs and Companies using RIVASTIGMINE ingredient

Market Authorisation Date: 06 July, 2007

Treatment: Treatment of alzheimer's dementia

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

EXELON family patents

19. Fuzeon patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6133418	ROCHE	Synthetic peptide inhibitors of HIV transmission	Nov, 2014 (9 years ago)

Drugs and Companies using ENFUVIRTIDE ingredient

Market Authorisation Date: 13 March, 2003

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

FUZEON family patents

20. Hepsera patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5663159	GILEAD	Prodrugs of phosphonates	Sep, 2014 (9 years ago)

Drugs and Companies using ADEFOVIR DIPIVOXIL ingredient

Market Authorisation Date: 20 September, 2002

Treatment: NA

Dosage: TABLET;ORAL

HEPSERA family patents

21. Humalog patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5474978	LILLY	Insulin analog formulations	Jun, 2014 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
NR(NR)	Oct 12, 2015

Drugs and Companies using INSULIN LISPRO RECOMBINANT ingredient

Market Authorisation Date: 15 November, 2019

Treatment: Humalog is an insulin analog that is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia

Dosage: INJECTABLE;INJECTION

HUMALOG family patents

22. Humalog Kwikpen patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5474978	LILLY	Insulin analog formulations	Jun, 2014 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
NR(NR)	Oct 12, 2015

Drugs and Companies using INSULIN LISPRO RECOMBINANT ingredient

Market Authorisation Date: 15 November, 2019

Treatment: Treatment of diabetes mellitus

Dosage: INJECTABLE;INJECTION

HUMALOG KWIKPEN family patents

23. Humalog Mix 50/50 patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5474978	LILLY	Insulin analog formulations	Jun, 2014 (9 years ago)

Drugs and Companies using INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT ingredient

Market Authorisation Date: 22 December, 1999

Treatment: Treatment of diabetes mellitus

Dosage: INJECTABLE;INJECTION

HUMALOG MIX 50/50 family patents

24. Humalog Mix 50/50 Kwikpen patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5474978	LILLY	Insulin analog formulations	Jun, 2014 (9 years ago)

Drugs and Companies using INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT ingredient

Market Authorisation Date: 22 December, 1999

Treatment: Treatment of diabetes mellitus

Dosage: INJECTABLE;INJECTION

HUMALOG MIX 50/50 KWIKPEN family patents

25. Humalog Mix 75/25 patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5474978	LILLY	Insulin analog formulations	Jun, 2014 (9 years ago)

Drugs and Companies using INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT ingredient

Market Authorisation Date: 22 December, 1999

Treatment: Treatment of diabetes mellitus

Dosage: INJECTABLE;INJECTION

HUMALOG MIX 75/25 family patents

26. Humalog Mix 75/25 Kwikpen patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5474978	LILLY	Insulin analog formulations	Jun, 2014 (9 years ago)

Drugs and Companies using INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT ingredient

Market Authorisation Date: 22 December, 1999

Treatment: Treatment of diabetes mellitus

Dosage: INJECTABLE;INJECTION

HUMALOG MIX 75/25 KWIKPEN family patents

27. Kaletra patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5648497	ABBVIE	Retroviral protease inhibiting compounds	Jul, 2014 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosing Schedule(D-124)	Apr 27, 2013

Drugs and Companies using LOPINAVIR; RITONAVIR ingredient

Market Authorisation Date: 09 November, 2007

Treatment: NA

Dosage: TABLET;ORAL; SOLUTION;ORAL

KALETRA family patents

28. Lantus patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5656722	SANOFI AVENTIS US	A21 -, B30 - modified insulin derivatives having an altered action profile	Aug, 2014 (9 years ago)

Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient

Market Authorisation Date: 27 April, 2007

Treatment: Treatment of diabetes mellitus

Dosage: INJECTABLE;INJECTION

LANTUS family patents

29. Letairis patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5703017	GILEAD	3-(Het) arylcarboxylic acid derivatives, their preparation and intermediates for their preparation	Dec, 2014 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jun 15, 2012
New Indication(I-716)	Oct 02, 2018
Orphan Drug Exclusivity(ODE)	Jun 15, 2014

Drugs and Companies using AMBRISENTAN ingredient

NCE-1 date: 16 June, 2011

Market Authorisation Date: 15 June, 2007

Treatment: NA

Dosage: TABLET;ORAL

LETAIRIS family patents

30. Levemir patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6869930	NOVO NORDISK INC	Acylated insulin	Feb, 2014 (10 years ago)
US6011007	NOVO NORDISK INC	Acylated insulin	Feb, 2014 (10 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-117)	May 18, 2015
M(M-115)	Apr 06, 2015

Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus

Dosage: INJECTABLE;SUBCUTANEOUS

LEVEMIR family patents

31. Levemir Flexpen patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6869930	NOVO NORDISK INC	Acylated insulin	Feb, 2014 (10 years ago)
US6011007	NOVO NORDISK INC	Acylated insulin	Feb, 2014 (10 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-117)	May 18, 2015
M(M-115)	Apr 06, 2015

Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus

Dosage: INJECTABLE;SUBCUTANEOUS

LEVEMIR FLEXPEN family patents

32. Levemir Innolet patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6869930	NOVO NORDISK INC	Acylated insulin	Feb, 2014 (10 years ago)
US6011007	NOVO NORDISK INC	Acylated insulin	Feb, 2014 (10 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-117)	May 18, 2015
M(M-115)	Apr 06, 2015

Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus

Dosage: INJECTABLE;SUBCUTANEOUS

LEVEMIR INNOLET family patents

33. Levemir Penfill patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6869930	NOVO NORDISK INC	Acylated insulin	Feb, 2014 (10 years ago)
US6011007	NOVO NORDISK INC	Acylated insulin	Feb, 2014 (10 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-117)	May 18, 2015
M(M-115)	Apr 06, 2015

Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus

Dosage: INJECTABLE;SUBCUTANEOUS

LEVEMIR PENFILL family patents

34. Lunesta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6444673	WOODWARD	Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it	Feb, 2014 (10 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
Pediatric Exclusivity(PED)	Apr 10, 2016
M(M-61)	Oct 10, 2015

Drugs and Companies using ESZOPICLONE ingredient

Market Authorisation Date: 15 December, 2004

Treatment: NA

Dosage: TABLET;ORAL

LUNESTA family patents

35. Micardis patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5591762	BOEHRINGER INGELHEIM	Benzimidazoles useful as angiotensin-11 antagonists	Jan, 2014 (10 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-612)	Oct 16, 2012

Drugs and Companies using TELMISARTAN ingredient

Market Authorisation Date: 04 April, 2000

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

MICARDIS family patents

36. Micardis Hct patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5591762	BOEHRINGER INGELHEIM	Benzimidazoles useful as angiotensin-11 antagonists	Jan, 2014 (10 years ago)

Drugs and Companies using HYDROCHLOROTHIAZIDE; TELMISARTAN ingredient

Market Authorisation Date: 17 November, 2000

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

MICARDIS HCT family patents

37. Minivelle patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6024976	NOVEN	Solubility parameter based drug delivery system and method for altering drug saturation concentration	Jan, 2014 (10 years ago)
US5646286	NOVEN	Palladium catalyzed vinylic substitution reactions with 2-substituted-pyridines	Aug, 2014 (9 years ago)
US5656286	NOVEN	Solubility parameter based drug delivery system and method for altering drug saturation concentration	Aug, 2014 (9 years ago)

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 23 September, 2014

Treatment: NA

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

MINIVELLE family patents

38. Moxeza patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5607942	HARROW EYE	7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives	Mar, 2014 (10 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Nov 19, 2013
Pediatric Exclusivity(PED)	May 19, 2014

Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient

Market Authorisation Date: 19 November, 2010

Treatment: Method of combating bacteria in a patient

Dosage: SOLUTION/DROPS;OPHTHALMIC

MOXEZA family patents

39. Naropin patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5834489	FRESENIUS KABI USA	Methods and compositions for the treatment of pain utilizing ropivacaine	May, 2014 (9 years ago)
US5670524	FRESENIUS KABI USA	Methods and compositions for the treatment of pain utilizing ropivacaine	Sep, 2014 (9 years ago)

Drugs and Companies using ROPIVACAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 04 January, 2011

Treatment: Method of treating pain using a pharmaceutically acceptable salt of ropivacaine and administering a composition containing less than 0.5% by weight of ropivacaine; Method of treating pain using a phar...

Dosage: SOLUTION;INJECTION

NAROPIN family patents

40. Natrecor patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5114923	SCIOS LLC	Recombinant techniques for production of novel natriuretic and vasodilator peptides	May, 2014 (9 years ago)

Drugs and Companies using NESIRITIDE RECOMBINANT ingredient

Market Authorisation Date: 10 August, 2001

Treatment: Method to induce natriuresis, diuresis and/or vasodilation

Dosage: FOR SOLUTION;INTRAVENOUS

NATRECOR family patents

41. Nexium patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6875872	ASTRAZENECA	Compounds	May, 2014 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-86)	Jun 18, 2012
Pediatric Exclusivity(PED)	Dec 18, 2012

Drugs and Companies using ESOMEPRAZOLE MAGNESIUM ingredient

Market Authorisation Date: 15 December, 2011

Treatment: NA

Dosage: FOR SUSPENSION, DELAYED RELEASE;ORAL; CAPSULE, DELAYED REL PELLETS;ORAL

NEXIUM family patents

42. Nexium 24hr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6875872	ASTRAZENECA LP	Compounds	May, 2014 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
RTO(RTO)	Mar 28, 2017

Drugs and Companies using ESOMEPRAZOLE MAGNESIUM ingredient

Market Authorisation Date: 28 March, 2014

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

NEXIUM 24HR family patents

43. Norvir patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5648497	ABBVIE	Retroviral protease inhibiting compounds	Jul, 2014 (9 years ago)

Drugs and Companies using RITONAVIR ingredient

Market Authorisation Date: 10 February, 2010

Treatment: NA

Dosage: TABLET;ORAL

NORVIR family patents

44. Novolog patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5618913	NOVO NORDISK INC	Insulin analogues	Jun, 2014 (9 years ago)

Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

NOVOLOG family patents

45. Novolog Flexpen patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5618913	NOVO NORDISK INC	Insulin analogues	Jun, 2014 (9 years ago)

Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

NOVOLOG FLEXPEN family patents

46. Novolog Flextouch patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5618913	NOVO NORDISK INC	Insulin analogues	Jun, 2014 (9 years ago)

Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

NOVOLOG FLEXTOUCH family patents

47. Novolog Innolet patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5618913	NOVO NORDISK INC	Insulin analogues	Jun, 2014 (9 years ago)

Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

NOVOLOG INNOLET family patents

48. Novolog Mix 50/50 patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5618913	NOVO NORDISK INC	Insulin analogues	Jun, 2014 (9 years ago)

Drugs and Companies using INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 26 August, 2008

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

NOVOLOG MIX 50/50 family patents

49. Novolog Mix 70/30 patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5618913	NOVO NORDISK INC	Insulin analogues	Jun, 2014 (9 years ago)

Drugs and Companies using INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 01 November, 2001

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

NOVOLOG MIX 70/30 family patents

50. Novolog Mix 70/30 Flexpen patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5618913	NOVO NORDISK INC	Insulin analogues	Jun, 2014 (9 years ago)

Drugs and Companies using INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 01 November, 2001

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

NOVOLOG MIX 70/30 FLEXPEN family patents

51. Novolog Mix 70/30 Penfill patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5618913	NOVO NORDISK INC	Insulin analogues	Jun, 2014 (9 years ago)

Drugs and Companies using INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 01 November, 2001

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

NOVOLOG MIX 70/30 PENFILL family patents

52. Novolog Penfill patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5618913	NOVO NORDISK INC	Insulin analogues	Jun, 2014 (9 years ago)

Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

NOVOLOG PENFILL family patents

53. Noxafil patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5703079	SCHERING	Tetrahydrofuran antifungals	Aug, 2014 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 15, 2011

Drugs and Companies using POSACONAZOLE ingredient

NCE-1 date: 15 September, 2010

Market Authorisation Date: 15 September, 2006

Treatment: Prophylaxis of invasive aspergillus and candida infections and treatment of oropharyngeal candidiasis

Dosage: SUSPENSION;ORAL

NOXAFIL family patents

54. Noxafil patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5703079	MERCK SHARP DOHME	Tetrahydrofuran antifungals	Aug, 2014 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	May 31, 2024
Orphan Drug Exclusivity(ODE-355)	Jun 17, 2028
New Indication(I-881)	Jun 17, 2024

Drugs and Companies using POSACONAZOLE ingredient

Market Authorisation Date: 25 November, 2013

Treatment: Prophylaxis of invasive aspergillus and candida infections

Dosage: TABLET, DELAYED RELEASE;ORAL; SOLUTION;INTRAVENOUS

NOXAFIL family patents

55. Prezista patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6248775	JANSSEN PRODS	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors	Aug, 2014 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
Pediatric Exclusivity(PED)	Jun 16, 2015
New Dosage Form(NDF)	Dec 16, 2014
New Dosing Schedule(D-135)	Feb 01, 2016

Drugs and Companies using DARUNAVIR ingredient

Market Authorisation Date: 16 December, 2011

Treatment: NA

Dosage: SUSPENSION;ORAL; TABLET;ORAL

PREZISTA family patents

56. Relenza patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6294572	GLAXOSMITHKLINE	Crystalline N-acetyl neuraminic acid derivatives and process for their preparation	Dec, 2014 (9 years ago)

Drugs and Companies using ZANAMIVIR ingredient

Market Authorisation Date: 26 July, 1999

Treatment: NA

Dosage: POWDER;INHALATION

RELENZA family patents

57. Surfaxin patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5407914	LEES PHARM HK	Pulmonary surfactant protein and related polypeptides	Nov, 2014 (9 years ago)

Drugs and Companies using LUCINACTANT ingredient

Market Authorisation Date: 06 March, 2012

Treatment: Prevention of respiratory distress (rds) in premature infants

Dosage: SUSPENSION;INTRATRACHEAL

SURFAXIN family patents

58. Twynsta patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5591762	BOEHRINGER INGELHEIM	Benzimidazoles useful as angiotensin-11 antagonists	Jan, 2014 (10 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Oct 16, 2012

Drugs and Companies using AMLODIPINE BESYLATE; TELMISARTAN ingredient

Market Authorisation Date: 16 October, 2009

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

TWYNSTA family patents

59. Varithena patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE38919	PROVENSIS	Injectable microfoam containing a sclerosing agent	Oct, 2014 (9 years ago)

Drugs and Companies using POLIDOCANOL ingredient

Market Authorisation Date: 21 December, 2017

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

VARITHENA family patents

60. Velcade patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6617317	TAKEDA PHARMS USA	Boronic ester and acid compositions	Oct, 2014 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE)	Oct 08, 2021
M(M-139)	Aug 08, 2017
M(M-165)	Sep 14, 2018
New Indication(I-695)	Oct 08, 2017
New Dosing Schedule(D-142)	Oct 08, 2017
New Dosing Schedule(D-141)	Oct 08, 2017
Orphan Drug Exclusivity(ODE-76)	Oct 08, 2021
Pediatric Exclusivity(PED)	Apr 08, 2022
NR(NR)	Jan 23, 2015

Drugs and Companies using BORTEZOMIB ingredient

Market Authorisation Date: 13 May, 2003

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

VELCADE family patents

61. Vigamox patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5607942	NOVARTIS	7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives	Mar, 2014 (10 years ago)

Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient

Market Authorisation Date: 15 April, 2003

Treatment: Method of combating bacteria in a patient

Dosage: SOLUTION/DROPS;OPHTHALMIC

VIGAMOX family patents

62. Vimovo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6875872	HORIZON	Compounds	May, 2014 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jul 06, 2020
New Combination(NC)	Apr 30, 2013

Drugs and Companies using ESOMEPRAZOLE MAGNESIUM; NAPROXEN ingredient

Market Authorisation Date: 30 April, 2010

Treatment: NA

Dosage: TABLET, DELAYED RELEASE;ORAL

VIMOVO family patents

63. Vimpat patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5654301	UCB INC	Amino acid derivative anticonvulsant	Aug, 2014 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosing Schedule(D-188)	Apr 28, 2026
New Patient Population(NPP)	Oct 14, 2024
New Dosing Schedule(D-144)	Aug 29, 2017
New Indication(I-696)	Aug 29, 2017
New Dosing Schedule(D-143)	Aug 29, 2017
New Indication(I-878)	Nov 16, 2023
New Chemical Entity Exclusivity(NCE)	Oct 28, 2013

Drugs and Companies using LACOSAMIDE ingredient

NCE-1 date: 28 October, 2012

Market Authorisation Date: 28 October, 2008

Treatment: Method of treating, as adjunctive therapy, partial-onset seizures in a patient with epilepsy aged 17 years and older

Dosage: TABLET;ORAL; SOLUTION;ORAL; SOLUTION;INTRAVENOUS

VIMPAT family patents

64. Welchol patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6066678	COSETTE	Process for removing bile salts from a patient and alkylated compositions therefor	Apr, 2014 (9 years ago)
US7101960	COSETTE	Process for removing bile salts from a patient and alkylated compositions therefor	Apr, 2014 (9 years ago)
US5917007	COSETTE	Process for removing bile salts from a patient and alkylated compositions therefor	Apr, 2014 (9 years ago)
US6784254	COSETTE	Process for removing bile salts from a patient and alkylated compositions therefor	Apr, 2014 (9 years ago)
US6433026	COSETTE	Process for removing bile salts from a patient and alkylated compositions therefor	Apr, 2014 (9 years ago)
US5919832	COSETTE	Amine polymer sequestrant and method of cholesterol depletion	Apr, 2014 (9 years ago)
US5693675	COSETTE	Alkylated amine polymers	Dec, 2014 (9 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-608)	Oct 02, 2012
Pediatric Exclusivity(PED)	Apr 02, 2013

Drugs and Companies using COLESEVELAM HYDROCHLORIDE ingredient

Market Authorisation Date: 26 May, 2000

Treatment: Use as a bile acid sequestrant for lowering cholesterol; Use as a bile acid sequestrant

Dosage: TABLET;ORAL; FOR SUSPENSION;ORAL

WELCHOL family patents

65. Zyvox patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5688792	PFIZER	Substituted oxazine and thiazine oxazolidinone antimicrobials	Nov, 2014 (9 years ago)

Drugs and Companies using LINEZOLID ingredient

Market Authorisation Date: 18 April, 2000

Treatment: Treatment of microbial infections

Dosage: FOR SUSPENSION;ORAL; TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
4.6 mg/24 hr and 9.5 mg/24 hr	27 Apr, 2011	1		08 Jan, 2019	Extinguished
13.3 mg/24 hr	22 Jan, 2013	1	31 Aug, 2015	08 Jan, 2019	Eligible

Strength	Dosage	Availability
4.6MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
9.5MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
13.3MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mg/25 mg and 200 mg/50 mg	23 Dec, 2008	1		10 Nov, 2020	Extinguished
80 mg/20 mg per mL	19 Jun, 2014	1	27 Dec, 2016	28 Nov, 2021	Deferred

Strength	Dosage	Availability
100MG;25MG	TABLET;ORAL	Prescription
80MG/ML;20MG/ML	SOLUTION;ORAL	Prescription
200MG;50MG	TABLET;ORAL	Prescription

Strength	Dosage	Availability
12.5MG;40MG	TABLET;ORAL	Prescription
25MG;80MG	TABLET;ORAL	Prescription
12.5MG;80MG	TABLET;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0375 mg/day 0.05 mg/day 0.075 mg/day 0.1 mg/day	18 Aug, 2014	1	15 Aug, 2018	04 Jul, 2030	Deferred
0.025 mg/day	08 May, 2015	1	15 Aug, 2018	04 Jul, 2030	Deferred

Strength	Dosage	Availability
0.0375MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
0.05MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
0.1MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
0.075MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2 mg/mL, 5 mg/mL and 10 mg/mL, 20 mL, 30 mL and 20 mL vials	13 Nov, 2006	1	17 Jul, 2014	23 Sep, 2014	Extinguished
2 mg/mL, 100 mL	30 Jan, 2015	1	13 Jul, 2016	28 Nov, 2026	Eligible
2 mg/mL, 200 mL	03 Sep, 2015	1	16 Mar, 2018	28 Nov, 2026	Extinguished

Strength	Dosage	Availability
150MG/20ML (7.5MG/ML)	SOLUTION;INJECTION	Prescription
20MG/10ML (2MG/ML)	SOLUTION;INJECTION	Prescription
100MG/10ML (10MG/ML)	SOLUTION;INJECTION	Prescription
100MG/20ML (5MG/ML)	SOLUTION;INJECTION	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
20 mg and 40 mg	05 Aug, 2005	1		01 Mar, 2008	Extinguished
20 mg and 40 mg	01 Aug, 2013	1		03 Nov, 2019	Extinguished
10 mg	06 Jul, 2018	1	23 Mar, 2020	03 Nov, 2019	Extinguished
2.5 mg and 5 mg	24 Sep, 2018	1		03 Nov, 2019	Extinguished

Strength	Dosage	Availability
EQ 5MG BASE/PACKET	FOR SUSPENSION, DELAYED RELEASE;ORAL	Prescription
EQ 10MG BASE/PACKET	FOR SUSPENSION, DELAYED RELEASE;ORAL	Prescription
EQ 20MG BASE/PACKET	FOR SUSPENSION, DELAYED RELEASE;ORAL	Prescription
EQ 40MG BASE/PACKET	FOR SUSPENSION, DELAYED RELEASE;ORAL	Prescription
EQ 20MG BASE	CAPSULE, DELAYED REL PELLETS;ORAL	Prescription
EQ 2.5MG BASE/PACKET	FOR SUSPENSION, DELAYED RELEASE;ORAL	Prescription
EQ 40MG BASE	CAPSULE, DELAYED REL PELLETS;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
20 mg	24 Apr, 2014
20 mg	09 Sep, 2016	1	05 Mar, 2019	03 Nov, 2019	Eligible

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
40 mg/mL	28 Feb, 2011	1		19 Jul, 2019	Extinguished
100 mg	16 Jun, 2014	1		19 Jul, 2019	Extinguished
18 mg/mL, 16.7 mL vials	24 Nov, 2015	1	25 May, 2022	04 Jul, 2031	Eligible

Strength	Dosage	Availability
100MG	TABLET, DELAYED RELEASE;ORAL	Prescription
300MG/16.7ML (18MG/ML)	SOLUTION;INTRAVENOUS	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
75 mg, 150 mg and 300 mg	23 Jun, 2010	1		26 Dec, 2026
400 mg	23 Jun, 2010	3		26 Dec, 2026
600 mg	23 Jun, 2010	4	21 Nov, 2017	26 Dec, 2026	Deferred
800 mg	14 May, 2013	1	29 Sep, 2022	26 Dec, 2026	Eligible

Strength	Dosage	Availability
EQ 10MG BASE;80MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
EQ 5MG BASE;80MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
EQ 10MG BASE;40MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
EQ 5MG BASE;40MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued

Strength	Dosage	Availability
EQ 20MG BASE;500MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, DELAYED RELEASE;ORAL	Discontinued
EQ 20MG BASE;375MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, DELAYED RELEASE;ORAL	Discontinued

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
10 mg/mL	29 Oct, 2012	3		17 Mar, 2022	Extinguished
50 mg, 100 mg, 150 mg, and 200 mg	29 Oct, 2012	14	17 Mar, 2022	17 Mar, 2022	Extinguished
10 mg/mL, 20 mL	30 Jun, 2016	1		17 Mar, 2022	Extinguished

Strength	Dosage	Availability
50MG	TABLET;ORAL	Prescription
10MG/ML	SOLUTION;ORAL	Prescription
100MG	TABLET;ORAL	Prescription
150MG	TABLET;ORAL	Prescription
200MG/20ML (10MG/ML)	SOLUTION;INTRAVENOUS	Prescription
200MG	TABLET;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1.875 g/Packet and 3.75 g/Packet	09 Apr, 2010	1		02 Dec, 2014	Extinguished
625 mg	01 Jul, 2009	1	16 May, 2018	10 Dec, 2014	Extinguished

Pharsight

Drug Patents Expiring in 2014

1. Abelcet patents expiration

ABELCET family patents

2. Abilify patents expiration

ABILIFY family patents

3. Abilify Maintena Kit patents expiration

ABILIFY MAINTENA KIT family patents

4. Alinia patents expiration

ALINIA family patents

5. Allegra patents expiration

ALLEGRA family patents

6. Allegra Allergy patents expiration

ALLEGRA ALLERGY family patents

7. Allegra Hives patents expiration

ALLEGRA HIVES family patents

8. Allegra-d 12 Hour Allergy And Congestion patents expiration

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION family patents

9. Allegra-d 24 Hour Allergy And Congestion patents expiration

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION family patents

10. Amitiza patents expiration

AMITIZA family patents

11. Angiomax patents expiration

ANGIOMAX family patents

12. Aptivus patents expiration

APTIVUS family patents

13. Children's Allegra Allergy patents expiration

CHILDREN'S ALLEGRA ALLERGY family patents

14. Children's Allegra Hives patents expiration

CHILDREN'S ALLEGRA HIVES family patents

15. Copaxone patents expiration

COPAXONE family patents

16. Duac patents expiration

DUAC family patents

17. Ertaczo patents expiration

ERTACZO family patents

18. Exelon patents expiration

EXELON family patents

19. Fuzeon patents expiration

FUZEON family patents

20. Hepsera patents expiration

HEPSERA family patents

21. Humalog patents expiration

HUMALOG family patents

22. Humalog Kwikpen patents expiration

HUMALOG KWIKPEN family patents

23. Humalog Mix 50/50 patents expiration

HUMALOG MIX 50/50 family patents

24. Humalog Mix 50/50 Kwikpen patents expiration

HUMALOG MIX 50/50 KWIKPEN family patents

25. Humalog Mix 75/25 patents expiration

HUMALOG MIX 75/25 family patents

26. Humalog Mix 75/25 Kwikpen patents expiration

HUMALOG MIX 75/25 KWIKPEN family patents

27. Kaletra patents expiration

KALETRA family patents

28. Lantus patents expiration

LANTUS family patents

29. Letairis patents expiration

LETAIRIS family patents

30. Levemir patents expiration

LEVEMIR family patents

31. Levemir Flexpen patents expiration

LEVEMIR FLEXPEN family patents

32. Levemir Innolet patents expiration

LEVEMIR INNOLET family patents

33. Levemir Penfill patents expiration

LEVEMIR PENFILL family patents

34. Lunesta patents expiration

LUNESTA family patents

35. Micardis patents expiration

MICARDIS family patents

36. Micardis Hct patents expiration

MICARDIS HCT family patents

37. Minivelle patents expiration

MINIVELLE family patents

38. Moxeza patents expiration

MOXEZA family patents

39. Naropin patents expiration

NAROPIN family patents

Strength	Dosage	Availability
625MG	TABLET;ORAL	Prescription
3.75GM/PACKET	FOR SUSPENSION;ORAL	Prescription
1.875GM/PACKET Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	FOR SUSPENSION;ORAL	Discontinued

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2 mg/mL, 100 mL bag	29 Dec, 2009	1	16 Jul, 2015	18 Nov, 2014	Extinguished
2 mg/mL, 300 mL bag	01 Sep, 2009	1	27 Jun, 2012	18 Nov, 2014	Deferred
100 mg/5 mL	03 Aug, 2009	1	03 Jun, 2015	29 Jan, 2021	Deferred
600 mg	21 Dec, 2005	1	18 May, 2015	18 Nov, 2014	Eligible

Strength	Dosage	Availability
100MG/5ML	FOR SUSPENSION;ORAL	Prescription
400MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
600MG	TABLET;ORAL	Prescription